Bydureon: weekly exenatide injection launched

A prolonged-release preparation of exenatide has been launched. Bydureon is administered at a dose of 2mg once weekly by subcutaneous injection. Both Bydureon and Byetta, the existing twice-daily preparation of exenatide, are licensed for use in combination with other oral hypoglycaemics in type II diabetes.

Bydureon has been investigated in 1525 patients in 4 key studies: 2 studies comparing exenatide twice daily against once weekly administration; 1 study comparing against sitagliptin or pioglitazone; and 1 study comparing with insulin glargine. Bydureon was more effective at reducing HBA1c levels than comparator treatment in all 4 studies.

Exenatide is contraindicated in renal impairment: Bydureon in patients with creatinine clearance less than 50ml/min; Byetta may be used with caution in these patients but is contraindicated if creatinine clearance is less than 30ml/min.

View Bydureon drug record

Further Information: Lilly Eli & Co

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases